Plain-English translation of NCT05759728 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called CNA3103, which uses your own immune cells (called CAR-T cells) that are specially engineered in a lab to recognize and attack colorectal cancer cells. The trial has two parts: first, researchers will find the safest and most effective dose, then they'll give that dose to more patients to confirm it works and is safe.
Advanced colorectal cancer that has spread to other parts of the body can be hard to treat, especially after standard chemotherapy treatments stop working. This medication represents a new approach using your body's own immune system to fight the cancer.
You likely qualify if…
You likely don't qualify if…
You would first have a tumor biopsy taken to confirm your cancer has the right marker for this treatment. Then your own immune cells would be collected and sent to a lab to be engineered. While your cells are being prepared, you'll receive lymphodepletion (medication to prepare your body). Finally, you'll receive a single intravenous infusion of the engineered cells on Day 0, followed by close monitoring visits to track how the treatment affects your cancer and any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Australia